Skip to main content
Log in

BCR-ABL TKI fluid retention-related AEs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • Huang J, et al. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study BMJ Open : 7 Aug 2023. Available from: URL: http://doi.org/10.1136/bmjopen-2022-071456

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

BCR-ABL TKI fluid retention-related AEs. Reactions Weekly 1969, 6 (2023). https://doi.org/10.1007/s40278-023-44472-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-44472-8

Navigation